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There is growing evidence of a relationship between inﬂammation and psychiatric illness. In particular,
the cytokine Interleukin-6 (IL-6) has been linked to stress-related disorders such as depression and
anxiety. Here we discuss evidence from preclinical and clinical studies examining the role of IL-6 in mood
disorders. We focus on the functional role of peripheral and central release of IL-6 on the development of
stress susceptibility and depression-associated behavior. By examining the contribution of both pe-
ripheral and central IL-6 to manifestations of stress-related symptomatology, we hope to broaden the
way the ﬁeld thinks about diagnosing and treating mood disorders.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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depression are not responsive to available antidepressant treat-
ments (Krishnan and Nestler, 2008). High rates of treatment
resistancemay be due to heterogeneity in biological mechanisms of
depression, such as increased inﬂammation, that are unaltered by
standard antidepressants. Despite numerous correlative studies
showing increased inﬂammation in depression, we still know little
about the mechanisms through which inﬂammation may trigger
depression or whether inﬂammation is simply a consequence of the
experience of depression. There is growing evidence that depres-
sion alters both the brain and the body of the individual. Many
patients with Major Depressive Disorder (MDD) have higher levels
of multiple inﬂammatory markers, including the cytokinet Mount Sinai, Department of
ew York, NY 10029, USA.
des).
n open access article under the CCInterleukin 6 (IL-6) (Maes et al., 1995 Bob et al., 2010; Dowlati et al.,
2010; Hodes et al., 2014). This cytokine is a small multifunctional
protein (Tanaka and Kishimoto, 2014), that can be released from a
myriad of tissues including white blood cells, endothelial cells,
epithelial cells, adipose tissue, astrocytes, microglia and neurons
(Coppack, 2001 Spooren et al., 2011; Rossi et al., 2015). IL-6 is pri-
marily categorized as a pro-inﬂammatory cytokine, but it also has
anti-inﬂammatory properties (Wolf et al., 2014). Recent research in
both preclinical (Hodes et al., 2014) and clinical models (Khandaker
et al., 2014; Hsu et al., 2015) has suggested a functional role for IL-6
in the development of depression and a potential for targeting it to
treat depression in humans. Here we discuss current research
examining the contribution of IL-6 to depression and stress-related
behavior.
1. IL-6 signaling and its role in inﬂammation
IL-6 belongs to a family of proteins that use GP130 as a signalBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Types of IL-6 signaling. A. Classical signaling only occurs in a few cells types found in the periphery. In classical signaling both the IL-6 receptor and gp130 signal transducer
are membrane bound. IL-6 binds to the receptor leading transcription that is thought to be anti-inﬂammatory. B. IL-6 trans-signaling can occur in any cell type that has membrane
bound gp130, all brain IL-6 signaling is thought to be trans-signaling. IL-6 bound to sIL-6R activates signaling through membrane bound gp130. Trans-signaling is thought to be pro-
inﬂammatory in part though its ability to activate more gp130 signal transducers compared to classical IL-6 signaling. C. Blockade of IL-6 signaling through soluble gp130. A soluble
form of gp130 can bind sIL-6R/IL-6 complexes and block trans-signaling. Soluble gp130 does not block classical IL-6 signaling.
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itory factor, leukemia inhibitory factors, cardiotrophin-1, neuro-
poietin, neurotrophin-1/B-cell stimulating factor 3 and oncostatin
M (Scheller et al., 2011; Murakami and Hirano, 2012). IL-6 signaling
is complex and can result in both inﬂammatory and anti-
inﬂammatory cascades depending upon the presence of either IL-
6 receptor (IL-6R) or the membrane bound gp130 signal trans-
ducer, which are expressed at very different frequencies within
speciﬁc cell types throughout the body.
Classical IL-6 signaling (Fig. 1a) is thought to be anti-
inﬂammatory (Wolf et al., 2014) and occurs through binding of
IL-6 to the membrane bound cell surface receptor. Classical IL-6
signaling only occurs on some subsets of T cells, hepatocytes,
megakaryocytes, neutrophils and monocytes (Scheller et al., 2011).
Additionally, IL-6 engages pro-inﬂammatory trans-signaling
(Fig. 1b) in which the soluble form of the IL-6 receptor (sIL-6R) is
shed from the membrane bound receptors (Lust et al., 1992;
Mullberg et al., 1993). The sIL-6R binds to IL-6 and is transported
to any cell type that expresses gp130 on its surface (Wolf et al.,
2014). While most soluble receptors, such as the soluble receptor
for tumor necrosis factor alpha (TNFa) result in antagonistic action
by competing for the ligand, the sIL-6R is agonistic and increases
the types of cells through which IL-6 can signal. In both classical
and trans-signaling, the IL-6/IL-6R/gp130 complex activates intra-
cellular signaling through the Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway and the mitogen-activated protein kinase (MAPK) pathway. There is evidence that
an imbalance away from the MAPK pathway via removal of regu-
lation by suppressor of cytokine signaling 3 (SOCS3) towards the
pro-inﬂammatory STAT3 signaling pathway contributes to auto-
immune disease (Tanaka and Kishimoto, 2014) and therefore may
also be a target for stress susceptibility (Fig. 2). Another method
through which circulating levels of IL-6 and its downstream
mechanisms are altered is via the soluble form of gp130. While sIL-
6R acts as an agonist, the soluble form of gp130 acts as an antag-
onist sequestering IL-6 and sIL-6R in blood (Wolf et al., 2014;
Garcia-Oscos et al., 2015), thereby stopping IL-6 from activating
trans-signaling but not classical signaling (Fig. 1c). Further research
is needed to determine whether stress alters soluble gp130 and its
potential use as an antidepressant.
A number of transcription factors directly regulate the IL-6 gene
including nuclear factor kappa B (NFkB), cAMP response element
binding protein (CREB), activator protein 1 (AP-1) and nuclear
factor for interleukin 6 (NF-IL6) (Dendorfer et al., 1994; Spooren
et al., 2011). The binding of NFkB to the wild type IL-6 promoter
in a variety of human cell types is necessary and sufﬁcient to
regulate IL-6 (Libermann and Baltimore, 1990 Zhang et al., 1990;
Ray and Prefontaine, 1994). Through trans-repression, glucocorti-
coid receptors (GR) can block the ability of NFkB to act as a tran-
scription factor, potentially comprising a method through which
stress modulates IL-6 levels (Ray and Prefontaine, 1994; De
Bosscher et al., 2000). Therefore, disruptions in the sensitivity of
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Fig. 2. Molecular proﬁles of classical IL-6 vs. trans-signaling. A. Classical IL-6 signaling leads to activation of the JAK/STAT, AKT and MAPK pathways to alter transcription. Release of
cytokines leads to feedback inhibition through SOCS. B. Trans-signaling creates a shift towards greater JAK/STAT signaling than MAPK through suppression of SOCS and alterations in
NFkB. This lack of feedback in concert with the increase in activation of JAK/STAT lead to greater transcription of cytokines and a pro-inﬂammatory state.
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response, independent of cortisol levels.
IL-6 has many functions within the immune system depending
upon which type of tissue it is acting upon, thereby contributing to
its role as both an inﬂammatory and anti-inﬂammatory cytokine.
IL-6 was originally discovered as a B cell stimulating factor, but was
also identiﬁed as a liver cell growth and stimulating factor (Tanaka
and Kishimoto, 2014) that can act to differentiate B-cells into
immunoglobulin producing plasma cells. IL-6 can also act on T
helper cells (Th/CD4þ cells), shifting naïve Th cells into the pro-
inﬂammatory Th17 subtype that suppresses the ability of TGF-b
to induce anti-inﬂammatory T-regulatory (Treg) cells (Murakami
and Hirano, 2012). Thus, activation of IL-6 leads to a pro-
inﬂammatory dominance in the proportion of Th17: Treg cells.
Furthermore, the presence of IL-17 released from Th17 cells acti-
vates a positive feedback loop through NFkB-IL-6 signaling, which
is considered an IL-6 ampliﬁer (Murakami and Hirano, 2012).
Within the peripheral and central nervous systems, IL-6 can act
as a neuronal growth factor leading to neurite development and
nerve regeneration (Spooren et al., 2011). However, this is highly
dependent upon circulating IL-6 levels, the type of neuron studied,
as well as age and inﬂammatory state of the animal. For example,
low concentrations of IL-6 in vitro reduced the survival of serotonin
neurons but had little effect on dopaminergic neurons, whereas
higher concentrations of IL-6 were detrimental only to dopami-
nergic neurons (Jarskog et al., 1997). Furthermore, low concentra-
tions of IL-6 from conditioned media of endotoxin-stimulated
astrocytes actually promoted the survival of dopaminergic neurons,
whereas high concentrations attenuated survival (Li et al., 2009).There are numerous ways that chronic alterations in IL-6 levels,
both within the periphery and the brain, may contribute to
depression symptomatology. Because IL-6 acts on somany different
target tissues throughout the body, dysregulation of this particular
cytokine can precipitate a multitude of events relevant to depres-
sion. While it is unlikely that IL-6 is acting alone to trigger the
symptoms of depression, blocking the effects of IL-6 can prevent
further escalation of inﬂammatory responses, as will be discussed
in more detail below.2. Relationship between IL-6 and major depressive disorder
Two recent meta analyses indicated that IL-6 is the most
consistently elevated cytokine in the blood of patients with MDD
(Dowlati et al., 2010; Haapakoski et al., 2015), corroborating
emerging evidence that IL-6 levels might serve as a predictive
biomarker. In antidepressant non-responders, peripheral levels of
IL-6 positively correlate with symptom severity (Lanquillon et al.,
2000). In healthy subjects undergoing psychosocial distress, low
peripheral IL-6 levels can predict earlier resolution of negative
mood (Virtanen et al., 2015). Individual differences in the IL-6
response to adverse conditions may have a genetic basis. Poly-
morphism of a single nucleotide on the IL-6 promoter (SNP
rs1800795) is thought to contribute to a heightened risk of
inﬂammation in individuals that are exposed to adverse socio-
economic environments (Cole et al., 2010). This occurs via b-
adrenergic activation of the erythroid transcription factor (GATA 1),
a mediator of red blood cell development and maturation. Another
polymorphism on the IL-6R gene (rs 8192284) leads to a functional
G.E. Hodes et al. / Neurobiology of Stress 4 (2016) 15e2218amino acid change altering the proteolytic cleavage site that
changes circulating levels of sIL-6r (Tanaka and Kishimoto, 2014). It
is possible that these genetic differences may contribute to an in-
dividual's stress sensitivity that may inform future bioassay
development.
There are implications that sex differences in the immune sys-
tem may contribute to the greater incidence of depression in
women (Kessler et al., 1993). The menstrual cycle alters circulating
levels of cytokines in healthy women with increases found in sIL-
6R, TNFa and IL-4 during the luteal phase (O'Brien et al., 2007b),
whichmay have implications for pre-menstrual dysphoric disorder.
A surge in the female gonadal hormones estrogen and progesterone
correlated with elevations of circulating levels of IL-4 and TNFa,
respectively. Women also had higher circulating levels of sIL-6R
and TNFa than males during both stages of the cycle (O'Brien
et al., 2007b). Women are more sensitive to depression and social
disconnection induced by exposure to the endotoxin lipopolysac-
charide (LPS) (Moieni et al., 2015). In women but not men, the
change in TNFa and IL-6 following LPS administration positively
correlated with increased feelings of social isolation, but therewere
no sex differences between males and females in the circulating
levels of IL-6 or TNFa in response to LPS (Moieni et al., 2015). Later
in life, post-menopausal women seem to have greater basal levels
of IL-6 and a larger IL-6 stress response than age matched men
(Endrighi et al., 2016), suggesting that the relationship between
gonadal hormones and cytokines is complicated and unlikely to be
directly correlative.
In the early 90's, Maes, Smith and colleagues examined the
relationship between the peripheral immune system and depres-
sion (Maes et al., 1992) and put forth a theory suggesting that im-
mune dysregulation contributed to behavioral symptoms of the
illness (Smith, 1991; Maes, 1995, 1999). In support of this hypoth-
esis, there have been numerous studies in patients with various
inﬂammatory conditions including rheumatoid arthritis (Joaquim
and Appenzeller, 2015 Matcham et al., 2015; Ryan and McGuire,
2015), multiple sclerosis (Hoang et al., 2016; Kallaur et al., 2015;
Marrie et al., 2015), and psoriasis (Walker et al., 2011 Rabin et al.,
2012; McDonough et al., 2014), demonstrating a relationship be-
tween inﬂammation and depressed mood. However, the relation-
ship between depression and inﬂammation in humans is largely
confounded by the likelihood that the symptoms of the disease
themselves contribute to mood changes.
A recent longitudinal study in humans provided the ﬁrst evi-
dence that peripheral inﬂammation predates the occurrence of
depression. Children with higher circulating levels of IL-6 at age 9
were at a 10% greater risk of developing MDD by age 18 than the
general population or children with low levels of IL-6 (Khandaker
et al., 2014). While these clinical data are promising, the best way
to directly explore the functional relationship between IL-6 and
depression is through stress based animal models of depression.
3. Peripheral IL-6 contributes to stress sensitivity
Within preclinical research, the basis for a functional relation-
ship between depression-like behavior and inﬂammation origi-
nated from studies examining sickness response to systemic
administration of LPS (Bluthe et al., 1992; Dantzer et al., 2008),
which triggers pro-inﬂammatory cytokine release. Following a
single systemic LPS injection, rodents exhibit decreased self care,
social interaction, locomotor activity and feeding over the subse-
quent 24 h period (Bluthe et al., 1992). Furthermore, LPS injection in
male rats produces increased anhedonia as measured by decreased
preference for saccharin and decreased sexual behavior (Yirmiya,
1996). However, as the expression of these behaviors is tied to in-
ﬂammatory activation by LPS and subsides following a return tobaseline, this syndrome is considered sickness behavior rather than
a valid model of depression (Dantzer et al., 2008).
Stress based preclinical models of depression and anxiety
demonstrate that IL-6 is elevated following the onset of depression-
associated behaviors. Rodents exposed to chronic mild stress
(CMS), a series of stressors presented in an unpredictable manner
over time, express anhedonia and increased circulating levels of
pro-inﬂammatory cytokines including IL-6 (Pan et al., 2006; Mutlu
et al., 2012). It should be noted some studies have found no sig-
niﬁcant change (Farooq et al., 2012) or even a decrease in peripheral
IL-6 (Mormede et al., 2002) following CMS. However, both of these
studies found increased brain levels of other inﬂammatory markers
and may reﬂect a time-dependent shift from peripheral to central
cytokine activation or even potentially transport of the peripheral
cytokines into the brain (Mormede et al., 2002; Farooq et al., 2012).
Peripheral and hippocampal levels of IL-6 were increased in a ro-
dent model of seasonal affective disorder in which depression-like
behavior was induced by 4 weeks of constant darkness (Monje
et al., 2011). IL-6 knockout mice were resistant to the develop-
ment of a depression-like phenotype following exposure to con-
stant darkness, suggesting a functional role for IL-6 in stress
susceptibility (Monje et al., 2011).
Not every individual exposed to prolonged or extreme stress
develops a psychiatric disorder (Russo et al., 2012). In humans,
resilience has been deﬁned as the ability to actively adapt to
stressful experience and avoid the negative social, biological and
psychological consequences of exposure (Russo et al., 2012; Pfau
and Russo, 2015). Within the context of animal models, we deﬁne
resilience as an active coping mechanism that allows the animal to
avoid the deleterious physiological and/or behavioral effects of
chronic stress (Hodes et al., 2015; Pfau and Russo, 2015). In contrast
to resilience, we deﬁne susceptibility as a passive coping response
that results in maladaptive behavioral and biological consequences
(Hodes et al., 2015). Our group has recently demonstrated that
differences in IL-6 levels in the innate peripheral immune system
predict vulnerability to repeated social defeat stress (RSDS) (Hodes
et al., 2014), a resident intruder-based stress model. In this model,
experimental mice are placed into the home cage of a larger,
sexually experienced, aggressive mouse each day for 10 days. The
larger mouse quickly establishes dominance through physical
interaction (Golden et al., 2011). Following RSDS, approximately
two thirds of mice exhibit depression-like phenotypes measured by
social avoidance, anhedonia, disruptions of the circadian system,
and metabolic changes (Krishnan et al., 2007) along with increased
activation of pro-inﬂammatory immune markers such as IL-6
(Hodes et al., 2014).
We found that IL-6 is elevated to a greater degree in the blood of
susceptible mice than resilient mice and that this elevation occurs
within 20 min of the ﬁrst social defeat. Even though there were no
baseline differences before mice were exposed to stress, we
discovered that the animals that later become susceptible had
higher numbers of circulating leukocytes and that those cells
released more IL-6 when stimulated via LPS ex vivo (Hodes et al.,
2014). To examine whether these individual differences in the pe-
ripheral immune system are causal to the development of stress
susceptibility, bonemarrow (BM)-derived hematopoietic stem cells
(HSCs) were removed from stress susceptible mice releasing high
IL-6 or from IL-6 knockout (IL-6/) mice and transplanted into
wild type mice whose own peripheral immune cells were lethally
irradiated. Lead shielding protected the brains of these animals,
preserving microglia. Stress-susceptible BM chimeras exhibited
increased social avoidance behavior after exposure to subthreshold
RSDS. IL-6/ BM chimeras, as well as those treated with a sys-
temic IL-6 monoclonal antibody, were resilient to RSDS, suggesting
that reduced production of IL-6 by circulating immune cells
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ﬁndings in a purely emotional stress paradigm with no physical
component, demonstrating that this is not simply a peripheral
response to physical trauma (Hodes et al., 2014). Recently, a second
study in rats exposed to a version of RSDS also found higher
circulating levels of pro-inﬂammatory cytokines, including IL-6,
only in the blood of animals that showed submissive behavior
during social interaction with an aggressor (Wood et al., 2015).
Data from a non-social stress based model, learned helplessness
(LH), corroborates a functional role for IL-6 in the development of
stress susceptibility. Here, subjects are exposed to a controllable or
uncontrollable stress, such as shock, and the ability to actively
escape a subsequent stressor is measured. Only approximately 20%
of animals that undergo the uncontrollable stress are susceptible
and develop LH, whereas the remaining responders are resilient
and do not show escape deﬁcits. Susceptible animals display
anhedonia and increased levels of circulating IL-6 (Yang et al.,
2015), while animals exposed to controllable stressors or resilient
animals do not show these same perturbations (Yang et al., 2015).
Furthermore, IL-6 knockout mice are resilient to acute stress
models, including the forced swim test (FST), tail suspension test
(TST) and LH (Chourbaji et al., 2006). Together, these studies indi-
cate that peripheral IL-6 has a functional role in the development of
depression-like behaviors. One possibility is that IL-6 in the pe-
riphery is targeting receptors in the brain although the detailed
mechanisms of how this would occur need to be elucidated.
4. Central IL-6 contributes to stress sensitivity
Clinical literature provides evidence of increased IL-6 in the
brain of patients with depression. Elevations of IL-6 in the cerebral
spinal ﬂuid (CSF) were found in older women with depression
(Kern et al., 2014), in patients with either depression or schizo-
phrenia (Sasayama et al., 2013), suicide attempters (Lindqvist et al.,
2009) and women experiencing post-partum depression (Bouﬁdou
et al., 2009). Interestingly, studies that examined both plasma and
CSF levels of IL-6 did not ﬁnd correlations between the measures,
suggesting that peripheral IL-6 levels do not necessarily directly
reﬂect central IL-6 levels (Bouﬁdou et al., 2009 Lindqvist et al.,
2009; Sasayama et al., 2013).
In animal models, increased levels of IL-6 have also been found
in many areas of the brain. Maternal deprivation leads to increased
levels of pro-inﬂammatory cytokines, including IL-6 in the CSF of
rats (Reus et al., 2015). Increased IL-6 mRNA is found in microglia
isolated directly from the brains of mice that have undergone a
variant of repeated social defeat stress (Ramirez et al., 2015).
Treatment with the antidepressant imipramine blocked social
avoidance behavior and reduced microglia IL-6 in animals exposed
to stress or those given a systemic injection of LPS (Ramirez et al.,
2015). Increased IL-6 protein was reported in the hippocampus of
rats that underwent chronic unpredictable stress (Tianzhu et al.,
2014) and was attenuated by chronic treatment with the antide-
pressant ﬂuoxetine or treatment with an alternative medicine
Cordycepin, a derivative of adenosine extracted from fungi shown
to have antidepressant efﬁcacy (Li et al., 2015). Within the pre-
frontal cortex, increased levels of IL-6 protein were reported in rats
exposed to uncontrollable shock that demonstrated LH behavior,
but not in animals that were resilient to the same stressor (Sukoff
Rizzo et al., 2012). There has also been some indication of sex dif-
ferences in vulnerability to stress mediated by IL-6 (Tonelli et al.,
2008). The authors (Tonelli et al., 2008) found that repeated
intra-nasal LPS administration in rats led to greater immobility in
the FST in females than males and this coincided with increased IL-
6 transcription in the hippocampus of females only.
Intracranial injection of IL-6 was pro-depressant across abehavioral test battery in mice independent of sickness behavior
(Sukoff Rizzo et al., 2012). Intracranial injection of IL-6 increased
protein levels of IL-6 in a number of brain areas including frontal
cortex, hippocampus and hypothalamus. Additionally, transgenic
mice that overexpressed IL-6 centrally also demonstrated increased
immobility behavior on the FST and TST similar to the animals that
received intra-cranial injections of IL-6. Both IL-6 antibody and
soluble gp130 were able to block the effects of IL-6 infusion on
immobility (Sukoff Rizzo et al., 2012). Work examining enhance-
ment of susceptibility to a virally induced mouse model of multiple
sclerosis by social stress (Meagher et al., 2007) has also demon-
strated that a centrally administered IL-6 antibody blocked the
stress induced increase in severity of symptoms. Additionally,
central injection of IL-6 in the absence of social stress was sufﬁcient
to increase symptom severity (Meagher et al., 2007).
Recent research suggests that IL-6 may act through trans-
signaling to increase the synaptic inhibition/excitation (E/I) ratio
on prefrontal cortical neurons (Garcia-Oscos et al., 2015). This effect
on E/I ratio was blocked by vagal nerve stimulation activating the
“anti-inﬂammatory reﬂex.” Intriguingly, systemic administration of
IL-6 was found to decrease extracellular dopamine levels in the
nucleus accumbens (NAc), an effect that was further potentiated by
a mild stress (Song et al., 1999) suggesting that peripheral sources
of IL-6 alter activity of brain reward circuitry. In addition, some of
the actions of central expression of IL-6 are likely mediated by its
effects on astrogliosis, microgliosis and blood brain barrier integrity
(Spooren et al., 2011), potentially resulting in greater peripheral
inﬁltration into the brain.
Within the brain, the interactions between NFkB and IL-6 may
also contribute to depression-associated behavior through effects
on synaptic plasticity (Christoffel et al., 2011a; Russo and Nestler,
2013). Inhibitor of kB kinase (IkK), which contributes to increased
NFkB signaling, is elevated in the NAc of susceptible mice that
undergo repeated social defeat stress (Christoffel et al., 2011b,
2012). Over-expression of a constitutively active form of IkK leads
to a number of depression- and anxiety-like behaviors including
increased social avoidance following a sub-threshold stress, passive
coping in the FST, increased anhedonia measured by decreased
sucrose preference (Christoffel et al., 2012) and increased explor-
atory based anxiety behavior measured in an open ﬁeld. Social
avoidance behavior is linked to an IkK-dependent increase in
excitatory synaptic plasticity within the NAc (Christoffel et al.,
2011b, 2012; Golden et al., 2013), however it remains to be deter-
mined whether NFkB is activated upstream through IL-6 to exert its
effects on NAc plasticity or depression-like behavior.
5. IL-6 and anti-inﬂammatory agents as a treatment for
depression
The interest in peripheral IL-6 as a mechanism for depression
has the potential to change how we treat mental disorders. A
number of humanizedmonoclonal antibody therapies are currently
undergoing clinical trials for treatment of mood disorders. Biologics
including humanized and chimeric IL-6 receptor antibodies (Toci-
lizumab) or IL-6 antibodies (Siltuximab/Sirukumab) are currently
in clinical trials or are already FDA approved to treat inﬂammatory
illnesses including rheumatoid arthritis, and Castleman's syndrome
(Venkiteshwaran, 2009; Williams, 2013). A recent trial of Sir-
ukumab conducted in patients with rheumatoid arthritis showed a
signiﬁcant alleviation of depressive symptoms (Smolen et al., 2014).
These types of therapies are now being considered for the treat-
ment of primary unipolar and bipolar depression (Brietzke et al.,
2011).
Traditional antidepressants have yielded mixed results
regarding their anti-inﬂammatory properties. Some studies report
G.E. Hodes et al. / Neurobiology of Stress 4 (2016) 15e2220that antidepressants reduce systemic inﬂammation (Sluzewska
et al., 1995; Hannestad et al., 2011), whereas some report no ef-
fects (Maes et al., 1995; Jazayeri et al., 2010). The type of antide-
pressant and dose may contribute to the variability of the effects of
antidepressants on cytokines. High doses of tricyclic antidepres-
sants have actually been shown to increase stimulated IL-6 release
ex-vivo in the blood of both patients with depression and healthy
controls (Kubera et al., 2004). Additionally, low doses of ﬂuoxetine
when presented in combination with 5-hydroxytryptophan also
increased IL-6 release under the same circumstances. Fluoxetine by
itself did not signiﬁcantly alter levels of IL-6 released over 48 h at
either dose (Kubera et al., 2004). Meta-analysis of in vivo studies
demonstrated that SSRIs, but not tricyclic antidepressants, reduced
circulating levels of IL-6 and IL-1b (Hannestad et al., 2011). Sex of
the patient also likely contributes to some of the variation in
treatment response as men, but not women, given serotonin-
norepinephrine reuptake inhibitors had increased levels of IL-6
and c-reactive protein (CRP) whereas SSRIs seemed to decrease
IL-6 levels in men only (Vogelzangs et al., 2012). It is interesting to
note that tricyclic antidepressants did not alter IL-6 in either males
or females, but they did increase CRP in both (Vogelzangs et al.,
2012).
Treatment resistant status of patients may also contribute to the
variation found in studies examining the effects of traditional an-
tidepressants on cytokines. This suggests the potential utility of
cytokine and cytokine receptor bio-assays to predict antidepressant
response. Increased peripheral levels of IL-6 prior to treatment are
an indicator of poor response (Lanquillon et al., 2000; O'Brien et al.,
2007a). Other cytokines and their receptors have also been impli-
cated in treatment resistance. Higher circulating levels of TNFa
(O'Brien et al., 2007a; Eller et al., 2008), macrophage inhibiting
factor and IL-1B were found in leukocytes of patients that did not
respond to antidepressants (Audet and Anisman, 2013; Cattaneo
et al., 2013). The same study found a reduction in IL-6 mRNA
following treatment in antidepressant responders (Cattaneo et al.,
2013). High basal CRP prior to treatment has also been associated
with positive treatment response to antidepressants (Harley et al.,
2010). Additionally, treatment of patients suffering depression
following heart attacks found that antidepressant behavioral
response was linked heavily to an increase in soluble TNFa receptor
1 as well as a small reduction in circulating levels of sIL-6R (Tulner
et al., 2011).
Animal models of depression are starting to be used to deter-
mine which cytokines may relate to antidepressant treatment
response. Transgenic overexpression of IL-6 in the frontal cortex
and hippocampus of mice blunted the antidepressant response to
ﬂuoxetine (Sukoff Rizzo et al., 2012) and this effect could be reca-
pitulated using intra-cranial infusion of IL-6. Another model of
antidepressant resistance generated by treating rats chronically
with adrenocorticotropic hormone (ACTH) prior to antidepressant
treatment with ketamine (Walker et al., 2015) suggested a rela-
tionship between circulating levels of TNFa and CRP but not IL-6 in
responsiveness to treatment. In humans, a growing literature sug-
gests that ketamine, decreases pro inﬂammatory cytokine levels
(De Kock et al., 2013). Together, studies in humans and animal
models present strong evidence that inﬂammation is altered in a
subset of depressed subjects and identify IL-6 as a novel target for
MDD treatment.
6. Conclusion
Given the pleiotropic nature of IL-6, its perturbation by chronic
stress or disease could easily result in numerous peripheral and
central consequences. While this makes IL-6 an interesting
biomarker and potential therapeutic target for mood relateddisorders, it also raises the possibility of potential side effects.
Therefore, while we should test the ability of antibodies to
sequester IL-6 and prevent it from acting in the brain, we must also
continuemore nuanced research into themechanisms contributing
to the increased circulating levels of IL-6 observed in stressed an-
imals and humans with depression. Currently, a large body of evi-
dence suggests that chronic increases of IL-6 in both the brain and
body are implicated in stress susceptibility. However, we lack un-
derstanding of the mechanisms by which IL-6 signaling and its
molecular components may contribute to depression manifesta-
tion. By studying the interface of peripheral cytokines and CNS
cellular processes contributing to depression, we may be able to
develop a new class of therapeutics to treat mood disorders by
sequestering and preventing these peripherally-derived inﬂam-
matory cytokines from acting on mood circuits in the brain.
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